Mycenax Biotech Inc. (TPEX:4726)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Biopharmaceutical Development and Manufacturing Services	683.92M	652.62M	732.28M	774.27M	665.34M
Biopharmaceutical Development and Manufacturing Services Growth	4.80%	-10.88%	-5.42%	16.37%	70.23%
Total	683.92M	652.62M	732.28M	774.27M	665.34M
Total Growth	4.80%	-10.88%	-5.42%	16.37%	70.23%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Taiwan	267.07M	156.13M	278.17M	101.36M	68.28M
Taiwan Growth	71.05%	-43.87%	174.45%	48.44%	-36.27%
Asia	369.87M	493.77M	325.58M	405.59M	-
Asia Growth	-25.09%	51.66%	-19.73%	-	-
America	6.56M	2.72M	7.07M	73.23M	-
America Growth	141.32%	-61.56%	-90.34%	-	-
Europe	40.44M	-	121.46M	194.10M	214.97M
Europe Growth	-	-	-37.43%	-9.71%	-
Republic of China	-	-	-	-	13.56M
Republic of China Growth	-	-	-	-	-68.73%
Japan	-	-	-	-	159.48M
Japan Growth	-	-	-	-	147.39%
United States	-	-	-	-	76.76M
United States Growth	-	-	-	-	46.87%
South Korea	-	-	-	-	129.06M
South Korea Growth	-	-	-	-	4.71%
Other	-	-	-	-	3.24M
Other Growth	-	-	-	-	819.03%
Total	683.92M	652.62M	732.28M	774.27M	665.34M
Total Growth	4.80%	-10.88%	-5.42%	16.37%	70.23%

Source: S&P Global Market Intelligence.